Omico names genomic profiling partners

After a formal tender process Omico has announced the laboratory partners selected to provide free comprehensive genomic profiling (CGP) for 25,000 Australians in the next phase of the Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) initiative.